Grunenthal expands use of BioClinica's Trident
BioClinica, a global provider of clinical trial management solutions, has announced international research-based pharmaceutical Grunenthal will utilize enhancements in Trident IWR/IVR for a global study on pain medication. The three year study will involve 350 patients at 80 sites across 17 countries.
The interactive web and voice response technology replaces a manual system for managing inventory, returns and accountability of controlled substances. Trident automates these tasks and assists companies in compliance with controlled substance regulations.
"We envision IRT systems becoming an integral part of our controlled substance studies," said Henk Dieteren, associate director. "Trident's ability to manage controlled substance inventory is crucial to meet strict regulatory requirements for conducting clinical trials that involve investigative compounds related to pain management."
Trident reduces the average time it takes to write, set up and validate IWR and IVR protocols from months to weeks. Trident supports all of a sponsor's clinical studies within a standardized data model that supports automatic drug pooling and reporting. By giving clinical trial sponsors the ability to monitor and maintain all their study protocols in one place, it is more efficient and cost-effective than developing specifications, programming and validating a new IWR system for each new study.